RankAlpha logo
Back to Rankings

IOVA

Iovance BiotherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The stock is depressed versus a median analyst target near $9.56 while Iovance now has a commercial product, a visible launch-conversion setup, and multiple registrational shots on goal beyond current melanoma use.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +19.8.
What can break
Amtagvi demand may not convert cleanly from center onboarding and Proleukin ordering into sustained infusion volume.
Momentum
62
Value
41
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $6.00 · Bear $2.20
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.80
Why
Momentum62 · Δ7d +19.8
Value41 · Δ7d -0.1
Sentiment33 · Δ7d -18.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
62
26% active weight
Current posture
7d trendImproving
Δ7d
+19.8
Δ21d
-1.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
33
34% active weight
Current posture
7d trendSoftening
Δ7d
-18.4
Δ21d
-16.0
Why this grade

Composite grade D. Momentum 61.6 / Value 41.1 / Sentiment 32.9

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$2.23B
Beta
0.77
Shares Out
446.5M
P/E (TTM) · Derived
-4.6
P/S (TTM)
3.88
P/FCF (TTM) · Derived
-6.17
Rev YoY
+44.8%
EPS YoY
-47.5%
Gross Margin
+25.0%
Op Margin
-166.3%
Net Debt
-$247.54M
Current Ratio
3.60
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology